US5508276A
(en)
*
|
1994-07-18 |
1996-04-16 |
Eli Lilly And Company |
Duloxetine enteric pellets
|
US5910319A
(en)
|
1997-05-29 |
1999-06-08 |
Eli Lilly And Company |
Fluoxetine enteric pellets and methods for their preparation and use
|
US6199021B1
(en)
|
1997-10-15 |
2001-03-06 |
Cc Kinetics, Inc. |
Method and apparatus for measuring power output of one powering a chain driven vehicle
|
ATE309196T1
(de)
*
|
1999-04-09 |
2005-11-15 |
Lilly Co Eli |
Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
|
US6503894B1
(en)
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
JP2005053781A
(ja)
*
|
2001-08-27 |
2005-03-03 |
Nagase & Co Ltd |
光学活性な3−(n−メチルアミノ)−1−(2−チエニル)−プロパン−1−オールの製造方法
|
US20040249170A1
(en)
*
|
2002-01-24 |
2004-12-09 |
Alfio Borghese |
Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
|
US7659409B2
(en)
|
2002-03-19 |
2010-02-09 |
Mitsubishi Chemical Corporation |
3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
|
WO2003078418A1
(fr)
*
|
2002-03-19 |
2003-09-25 |
Mitsubishi Chemical Corporation |
Compose de 3-hydroxy-3-(2-thienyl)propionamide, procede de fabrication correspondant, et procede de fabrication d'un compose de 3-amino-1-(2-thienly)1-propanol a partir de ce dernier
|
DE10212301A1
(de)
*
|
2002-03-20 |
2003-10-02 |
Bayer Ag |
Verfahren zur Herstellung von Aryl-aminopropanolen
|
US20060167278A1
(en)
*
|
2002-05-20 |
2006-07-27 |
Mitsubishi Rayon Co. Ltd. |
Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives
|
WO2004005239A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Lonza Ag |
PROCESS FOR THE PREPARATION OF N-MONOSUBSTITUTED β-AMINO ALCOHOLS
|
US20050256318A1
(en)
*
|
2002-07-09 |
2005-11-17 |
Dominique Michel |
Process for the preparation of n-monosubstituted beta-amino alcohols
|
FR2841899A1
(fr)
*
|
2002-07-05 |
2004-01-09 |
Ppg Sipsy |
Procede de resolution asymetrique d'un racemique faisant intervenir l'acide diprogulique et utilisation dudit acide comme agent de resolution asymetrique
|
WO2004005307A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Lonza Ag |
Process for the preparation of optically active 3-n-methylamino-1-(2-thienyl)-1-propanol
|
DE10235206A1
(de)
*
|
2002-08-01 |
2004-02-19 |
Basf Ag |
Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol
|
CA2493776C
(en)
*
|
2002-08-06 |
2011-05-17 |
Sumitomo Seika Chemicals Co., Ltd. |
Process for producing n-monoalkyl-3-hydroxy-3-(2-thienyl)propanamine and intermediate
|
DE10237246B3
(de)
*
|
2002-08-14 |
2004-01-22 |
Consortium für elektrochemische Industrie GmbH |
(S)-3-Methylamino-1-(2-thienyl)-1-propanol-(-)-2,3,4,6-Di-O-isopropyliden-2-keto-L-gulonsäuresalz, Verfahren zu dessen Herstellung, dessen Verwendung sowie ein Verfahren zur Enantiomerenanreicherung von (S)-3-Methylamino-1-(2-thienyl)-1-propanol
|
GB0221438D0
(en)
*
|
2002-09-16 |
2002-10-23 |
Avecia Ltd |
Processes and compounds
|
AU2003276066A1
(en)
*
|
2002-10-07 |
2004-04-23 |
Lonza Ag |
Processes and intermediates for the preparation of optically active 3-amino-1-(2-thienyl)-1-propanol derivatives
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
GB0229583D0
(en)
*
|
2002-12-19 |
2003-01-22 |
Cipla Ltd |
A process for preparing duloxetine and intermediates for use therein
|
DE10302595A1
(de)
*
|
2003-01-22 |
2004-07-29 |
Basf Ag |
3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung
|
AU2003263585A1
(en)
*
|
2003-08-25 |
2005-03-10 |
Hetero Drugs Limited |
Amorphous duloxetine hydrochloride
|
DE10345772A1
(de)
*
|
2003-10-01 |
2005-04-21 |
Basf Ag |
Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
|
DE102004004719A1
(de)
*
|
2004-01-29 |
2005-08-18 |
Basf Ag |
Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
|
NZ549381A
(en)
|
2004-02-19 |
2010-05-28 |
Lonza Ag |
Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
|
US20050197503A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Boehringer Ingelheim International Gmbh |
Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
|
CN1300137C
(zh)
*
|
2004-03-31 |
2007-02-14 |
上海医药工业研究院 |
(s)-(+)-n,n-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺的制备方法
|
DE102004022686A1
(de)
|
2004-05-05 |
2005-11-24 |
Basf Ag |
Verfahren zur Herstellung optisch aktiver Alkohole
|
GB0410470D0
(en)
*
|
2004-05-11 |
2004-06-16 |
Cipla Ltd |
Pharmaceutical compound and polymorphs thereof
|
CZ297555B6
(cs)
*
|
2004-10-26 |
2007-02-07 |
Zentiva, A. S. |
Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
|
CZ297560B6
(cs)
*
|
2004-10-26 |
2007-02-07 |
Zentiva, A. S. |
Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
|
JP2007523213A
(ja)
*
|
2004-12-23 |
2007-08-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
|
WO2006081515A2
(en)
*
|
2005-01-27 |
2006-08-03 |
Teva Pharmaceutical Industries Ltd. |
Duloxetine hydrochloride polymorphs
|
US7399871B2
(en)
*
|
2005-03-08 |
2008-07-15 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
|
TW200639162A
(en)
*
|
2005-03-14 |
2006-11-16 |
Teva Pharma |
Pure duloxetine hydrochloride
|
WO2006126213A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Matrix Laboratories Ltd |
An improved process for the preparation of duloxetine
|
CN100364986C
(zh)
*
|
2005-07-14 |
2008-01-30 |
上海艾力斯医药科技有限公司 |
S-(+)-n,n-二甲基-3-(1-萘基氧基)-3-(2-噻吩基)丙胺的制备方法
|
EP1916243B1
(en)
|
2005-08-19 |
2012-05-16 |
Sumitomo Seika Chemicals Co., Ltd. |
(E)-N-Monoalkyl-3-oxo-3-(2-thienyl)propenamine and process for producing the same and (E,Z)-N-monoalkyl-3-oxo-3-(2-thienyl)propenamine and process for producing the same
|
EP1838692A2
(en)
*
|
2005-09-22 |
2007-10-03 |
Teva Pharmaceutical Industries Ltd |
Dnt-maleate and methods of preparation thereof
|
US20080207923A1
(en)
*
|
2005-09-22 |
2008-08-28 |
Santiago Ini |
Pure DNT-maleate and methods of preparation thereof
|
AU2006299833B2
(en)
|
2005-10-12 |
2012-04-12 |
Besins Healthcare Luxembourg Sarl |
Improved testosterone gel and method of use
|
EP2100888A3
(en)
*
|
2005-12-05 |
2011-01-19 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of duloxetine hydrochloride
|
EP1971592B1
(en)
*
|
2005-12-12 |
2011-04-27 |
Medichem, S.A. |
Improved synthesis and preparations of duloxetine salts
|
CN1304360C
(zh)
*
|
2005-12-12 |
2007-03-14 |
天津大学 |
N,n-二甲基-3-羟基-3-芳基丙胺的制备方法
|
DE102005062661A1
(de)
*
|
2005-12-23 |
2007-08-16 |
Basf Ag |
Verfahren zur Herstellung von optisch aktivem (1S)-3-Chlor-(-thien-2-yl)-propan-1-ol
|
DE102005062662A1
(de)
|
2005-12-23 |
2007-06-28 |
Basf Ag |
Verfahren zur Herstellung optisch aktiver Alkohole
|
CZ299270B6
(cs)
*
|
2006-01-04 |
2008-06-04 |
Zentiva, A. S. |
Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
|
US8362279B2
(en)
|
2006-01-06 |
2013-01-29 |
Msn Laboratories Limited |
Process for pure duloxetine hydrochloride
|
US7538232B2
(en)
|
2006-01-19 |
2009-05-26 |
Eli Lilly And Company |
Process for the asymmetric synthesis of duloxetine
|
US20070173541A1
(en)
*
|
2006-01-23 |
2007-07-26 |
Santiago Ini |
DNT-succinate and methods of preparation thereof
|
US20070191471A1
(en)
*
|
2006-01-23 |
2007-08-16 |
Santiago Ini |
DNT-fumarate and methods of preparation thereof
|
EP1856088A1
(en)
*
|
2006-01-23 |
2007-11-21 |
Teva Pharmaceutical Industries Ltd |
Dnt-benzenesulfonate and methods of preparation thereof
|
WO2007095200A2
(en)
*
|
2006-02-13 |
2007-08-23 |
Teva Pharmaceutical Industries Ltd. |
A process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate
|
EP1820800A1
(en)
|
2006-02-17 |
2007-08-22 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Crystalline forms of duloxetine hydrochloride and processes for their preparation
|
US7560573B2
(en)
*
|
2006-02-21 |
2009-07-14 |
Teva Pharmaceutical Industries Ltd |
Process for the preparation of (S)-(-)-N,N-dimethyl-3-(2-thienyl)-3-hydroxypropananine, a duloxetine intermediate
|
EP1826204A1
(en)
|
2006-02-28 |
2007-08-29 |
Laboratorios Del Dr. Esteve, S.A. |
Process for obtaining enantiomers of duloxetine precursors
|
WO2007123900A2
(en)
*
|
2006-04-17 |
2007-11-01 |
Teva Pharmaceutical Industries Ltd. |
Enantiomers of n,n-dimethyl-3-(2-thienyl)-3-hydroxypropanamine borane as intermediates in the synthesis of duloxetine
|
EP1857451B1
(en)
*
|
2006-05-05 |
2010-07-21 |
Fidia Farmaceutici S.p.A. |
A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine
|
WO2007134168A2
(en)
*
|
2006-05-10 |
2007-11-22 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing duloxetine
|
ITMI20060984A1
(it)
*
|
2006-05-18 |
2007-11-19 |
Dipharma Spa |
Procedimento per la preparazione di arilossipropilammine
|
WO2007139984A2
(en)
*
|
2006-05-23 |
2007-12-06 |
Teva Pharmaceutical Industries Ltd. |
Duloxetine hcl polymorphs
|
WO2007143065A2
(en)
*
|
2006-05-31 |
2007-12-13 |
Teva Pharmaceutical Industries Ltd. |
Process for preparing duloxetine and intermediates thereof
|
GB0612506D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Arrow Int Ltd |
Crystalline duloxetine hydrochloride
|
GB0612509D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Arrow Int Ltd |
Crystalline duloxetine hydrochloride
|
GB0612508D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Arrow Int Ltd |
Crystalline duloxetine hydrochloride
|
EP2044049A2
(en)
|
2006-07-03 |
2009-04-08 |
Ranbaxy Laboratories Limited |
Process for the preparation of enantiomerically pure salts of n-methyl- 3 -( 1-naph-thaleneoxy)- 3 - (-2-thienyl) propanamine
|
US20100261775A1
(en)
*
|
2006-07-03 |
2010-10-14 |
Sujoy Biswas |
Polymorphic form of duloxetine hydrochloride
|
CZ300116B6
(cs)
*
|
2006-12-05 |
2009-02-11 |
Zentiva, A. S. |
Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
|
EP2114912B1
(en)
*
|
2006-12-22 |
2012-04-04 |
Synthon B.V. |
Process for making duloxetine and related compounds
|
WO2008081476A2
(en)
*
|
2006-12-29 |
2008-07-10 |
Cadila Healthcare Limited |
Process for preparing duloxetine hydrochloride
|
WO2008093360A2
(en)
*
|
2007-01-31 |
2008-08-07 |
Usv Limited |
A process for preparation of (s)-(+)-n-methyl-3(1-naphthyloxy)-3(2-thienyl)propylamine hydrochloride
|
WO2008107911A2
(en)
*
|
2007-03-05 |
2008-09-12 |
Lupin Limited |
Novel process for preparation of duloxetine hydrochloride
|
AU2008252631B2
(en)
*
|
2007-05-18 |
2012-12-20 |
Cipla Limited |
Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the S-isomer
|
US20090017113A1
(en)
*
|
2007-07-13 |
2009-01-15 |
Osinga Niels J |
Duloxetine formulations
|
EP2060559A1
(en)
|
2007-11-19 |
2009-05-20 |
Cadila Pharmaceuticals Limited |
Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers
|
WO2009087463A2
(en)
*
|
2007-12-26 |
2009-07-16 |
Orchid Chemicals & Pharmaceuticals Limited |
A method for the preparation of duloxetine hydrochloride
|
WO2009092129A1
(en)
|
2008-01-25 |
2009-07-30 |
Alpharma Pty Ltd |
Delayed release pharmaceutical composition of duloxetine
|
EP2107057A1
(en)
|
2008-04-04 |
2009-10-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of pure duloxetine hydrochloride
|
CN105566284A
(zh)
*
|
2008-04-11 |
2016-05-11 |
尼克塔治疗公司 |
低聚物-芳氧基-取代的丙胺共轭物
|
WO2009130708A2
(en)
*
|
2008-04-22 |
2009-10-29 |
Shodhana Laboratories Limited |
Preparation of duloxetine and its salts
|
US20110230666A1
(en)
*
|
2008-06-03 |
2011-09-22 |
Shodhana Laboratories Limited |
process for the separation of enantiomerically pure compounds
|
EP2133072A1
(en)
|
2008-06-13 |
2009-12-16 |
KRKA, D.D., Novo Mesto |
Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
|
WO2010025238A2
(en)
|
2008-08-27 |
2010-03-04 |
Codexis, Inc. |
Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
|
WO2010025287A2
(en)
|
2008-08-27 |
2010-03-04 |
Codexis, Inc. |
Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
|
CA2758736A1
(en)
*
|
2009-01-06 |
2010-07-15 |
Alembic Pharmaceuticals Limited |
An improved process for the reparation of duloxetine and salts thereof
|
WO2010103443A1
(en)
*
|
2009-03-13 |
2010-09-16 |
Alembic Limited |
A process for the preparation of duloxetine hydrochloride
|
CZ304602B6
(cs)
|
2009-09-02 |
2014-07-30 |
Zentiva, K. S. |
Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
|
WO2011033366A2
(en)
|
2009-09-16 |
2011-03-24 |
Jubilant Life Sciences Limited |
Process for the preparation of duloxetine hydrochloride and its precursors
|
WO2011077443A1
(en)
*
|
2009-12-22 |
2011-06-30 |
Biocon Limited |
An improved process for the preparation of duloxetine hydrochloride
|
WO2011128370A1
(en)
*
|
2010-04-13 |
2011-10-20 |
Krka, D.D., Novo Mesto |
Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof
|
US20130053579A1
(en)
|
2010-05-18 |
2013-02-28 |
Arch Pharmalabs Limited |
Process for the preparation of n-methyl-o-aryloxy propanamine derivatives and pharmaceutically acceptable salt thereof
|
US9859510B2
(en)
|
2015-05-15 |
2018-01-02 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
US11011709B2
(en)
|
2016-10-07 |
2021-05-18 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
MX2021003653A
(es)
|
2018-10-11 |
2021-06-23 |
Sanifit Therapeutics S A |
Inositol fosfatos para el tratamiento de calcificacion ectopica.
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
CN114163415B
(zh)
*
|
2021-12-01 |
2023-03-03 |
珠海润都制药股份有限公司 |
一种盐酸度洛西汀中间体的制备方法
|
CN115286613B
(zh)
*
|
2022-10-08 |
2023-01-31 |
潍坊市海欣药业有限公司 |
一种盐酸度洛西汀的制备方法
|